| Document |
Document Title |
|
WO/2024/062127A1 |
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispe...
|
|
WO/2024/063715A1 |
Effervescent Tablet Comprising L-Arginine Used for Healing Wounds The invention relates to a composition comprising L-arginine and a production method of said composition for use as a food supplement in order to heal wounds.
|
|
WO/2024/063480A1 |
The present invention relates to a pharmaceutical composition for moisturizing the skin or treating diseases in which skin barrier are weakened, comprising an RhoA-activating factor as an active ingredient. The present invention relates ...
|
|
WO/2024/063661A1 |
The subject matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children.
|
|
WO/2024/062238A1 |
The present invention relates to a composition comprising a heterotrophic skin bacterium and/or heterotrophic skin bacterial extract for use in the modulation of cytokine expression in a skin cell. The composition is particularly suited ...
|
|
WO/2024/063424A1 |
The present invention relates to microspheres comprising baricitinib, a method for producing same, and a pharmaceutical composition comprising same. The microspheres comprising baricitinib, according to the present invention, exhibit sta...
|
|
WO/2024/061894A1 |
The present disclosure relates to the use of compounds such as compounds of Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, ...
|
|
WO/2024/064898A2 |
Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
|
|
WO/2024/061187A1 |
Provided in the present disclosure are stilbene derivatives, a preparation method therefor and the use thereof. Specifically, provided in the present disclosure is the use of compounds represented by formula (I-1), and stereoisomers, pha...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/064947A1 |
Disclosed herein are compositions and methods for inhibiting pigmentation of hair or skin. The compositions of the disclosure comprise an effective amount of a compound used for inhibition of pigmentation.
|
|
WO/2024/062023A1 |
A Neem tree leaf extract of the present invention is enriched in Nimbolide and/or depleted in Azadirachtin content compared to the relative average proportional content of these components in Neem tree leaves. A method for producing such...
|
|
WO/2024/062675A1 |
Provided are: a stratum corneum formation promoter that promotes stratum corneum formation through the activation of olfactory receptors; a skin roughness inhibitor; a moisturizing agent; a skin barrier function improving agent; a melani...
|
|
WO/2024/061118A1 |
The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
|
|
WO/2024/063348A1 |
A pharmaceutical composition for thyroid protection, according to the present invention, comprises potassium iodide, an excipient and a lubricant, wherein the average particle size of potassium iodide is less than 1.0 mm. The pharmaceuti...
|
|
WO/2024/061202A1 |
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibit...
|
|
WO/2024/063132A1 |
Provided are an antibacterial composition containing bacteria that exhibit antibacterial properties against bacteria having a positive correlation with a SCORAD value indicating the severity of atopic dermatitis, and a method for determi...
|
|
WO/2024/059559A1 |
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or co...
|
|
WO/2024/056568A1 |
The present invention relates to a composition comprising cysteamine, azabenzene-4-carboxamide and glycolic acid. The present invention also relates to the cosmetic use thereof for inhibiting, reducing or preventing skin pigmentation and...
|
|
WO/2024/056979A1 |
The invention relates to a hybrid molecule comprising at least one antibody Fc portion covalently bound to at least one peptide binding to a self-reactive lymphocyte involved in autoimmune vasculitis, to the uses of such a hybrid molecul...
|
|
WO/2024/057288A1 |
Methods are provided for treating acne vulgaris in subjects having acne vulgaris and oily skin and for treating truncal acne. Compositions comprising tazarotene or a pharmaceutically acceptable salt of tazarotenic acid in an oily-in-wate...
|
|
WO/2024/057096A1 |
A self-replicating saRNA expressing IL-31 or its fragments or variants, IL31RA, Oncostatin M receptor β, compositions formulated for administering the saRNA to a subject in need thereof, and methods for treating atopic dermatitis and ot...
|
|
WO/2024/057970A1 |
Disclosed is a composition for promoting expression of CCN2. This composition comprises green tea extract.
|
|
WO/2024/056978A1 |
The invention relates to a hybrid molecule comprising at least one antibody Fc portion covalently bound to at least one peptide binding to a self-reactive lymphocyte responsible for autoimmune dermatitis, the uses of such a hybrid molecu...
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/059186A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.The present invention provides isoquinoline derivatives of for...
|
|
WO/2024/057032A1 |
System and method for skin treatment A method of skin treatment comprising the steps of applying a topically active compound to a skin region of a person and applying light to the skin region, wherein the applied light has one or more wa...
|
|
WO/2024/058193A1 |
The present invention addresses the problem of providing a composition for an external preparation for skin, the composition: containing an ester-based steroid and gamma oryzanol, both the ester-based steroid component and the gamma oryz...
|
|
WO/2024/054929A1 |
The present application provides anti-VISTA constructs that bind to VISTA (e.g., anti-VISTA antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-VISTA, vectors comprising the nucleic acid molecules, host cells ...
|
|
WO/2024/054402A1 |
A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit elastase activi...
|
|
WO/2024/054157A1 |
An anti-IL-13Rαl antibody or an antigen binding fragment thereof and pharmaceutical formulations comprising same for use in treating patients with skin disorders, like atopic dermatitis, experiencing sleep loss or sleep disturbance caus...
|
|
WO/2024/054851A1 |
The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/052827A1 |
The disclosure provides methods for treating or preventing inflammatory conditions of the skin and methods of controlling and maintaining skin microbiota homeostasis, comprising administering a topical formulation comprising arabinose, i...
|
|
WO/2024/052922A1 |
An isolated antibody that binds to a cyclized peptide having an amino acid sequence as set forth in SEQ ID NO: 9 with an EC50 of less than 500 nM, as determined by ELISA is disclosed. Uses of same are also disclosed as well as methods of...
|
|
WO/2024/050599A1 |
The disclosure of the present invention relates to methods, uses and compositions for the treatment of psoriasis, psoriatic arthritis and dermatitis with pentosan polysulfate, or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/052914A1 |
The invention provides compositions comprising a modulator of a voltage dependent anion channel isoform VDAC1, 2 or 3 and methods for treating a group of rare autoimmune blistering skin conditions resulting from defective epidermal and m...
|
|
WO/2024/052789A1 |
It is the object of the present invention a composition for the treatment of acne.
|
|
WO/2024/051666A1 |
Disclosed are a dibenzylbutyrolactone glycoside compound as shown in formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing same, and ...
|
|
WO/2024/053625A1 |
The purpose of the present invention is to provide a means for shortening the time of development of the action of a local anesthetic agent, an antihistamine drug or the like against skin and oral mucosa. Provided are: a minute project...
|
|
WO/2024/054155A1 |
The present invention relates to cell biology. In particular, the present invention teaches methods of contacting the cells with a LING complex inhibitor to inhibit durotaxis and, in consequence, reduce fibrosis and metastasis. Methods o...
|
|
WO/2024/054868A1 |
Provided herein, in certain aspects, are methods for treating plaque psoriasis or atopic dermatitis comprising administration of an interleukin-2 (IL-2) Fc fusion protein.
|
|
WO/2024/051687A1 |
A pirfenidone topical formulation is provided, comprising a therapeutically effective amount of pirfenidone, water, and at least one cosolvent, the cosolvent being selected from a combination of dimethyl sulfoxide and an alcohol solvent....
|
|
WO/2024/054403A1 |
A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit collagenase act...
|
|
WO/2024/052756A1 |
The present invention concerns the use of a Sichuan pepper extract and a composition comprising said extract, for a cosmetic and/or dermatological treatment, in particular a topical treatment. The extract according to the invention has m...
|
|
WO/2024/052445A1 |
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is the CXCR3 antagonist 1-{(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4- (2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazi...
|
|
WO/2024/047645A1 |
A cosmetic or cosmeceutical composition (or formulation) comprising a liposome or a plurality of liposomes and a cosmetically acceptable carrier is provided. At least a portion of the liposomes are made of one or more bilayer-forming lip...
|
|
WO/2024/049959A1 |
Personal care compositions and methods for improving skin are disclosed. A personal care composition according to an aspect of the disclosure that may be in the form of an intimate care product and include from about 0.5 to about 7 wt.% ...
|
|
WO/2024/048489A1 |
Provided is an agent that can induce a retinol-like action while reducing the suppression of epidermal keratinocyte differentiation. The agent is applicable to human skin and the like. The agent for use to induce retinol-like action ac...
|
|
WO/2024/048831A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory skin diseases, the composition containing sibiriaester B as an active ingredient. Sibiriaester B was found to not exhibit cytotoxicity ...
|
|
WO/2024/050434A1 |
The present invention is directed to methods of treating certain diseases comprising administering compounds or pharmaceutical compositions of Formula (I), Formula (Ia), or a pharmaceutically acceptable salt, solvate or hydrate thereof. ...
|
